This year, EpiVax was awarded $243,561 in Total Direct and Indirect Funding to support the development of their unique HIV vaccine platform (de-tolerized anti-Dec205). The total amount awarded to date is $797,855 in Direct and Indirect costs, to further this aspect of the GAIA Vaccine development program.
Recent Posts
- Amsterdam Immunogenicity and Tolerance Seminar- 2024
- Westin Immunogenicity Seminar & Computational Vaccinology Symposium- 2024
- Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development
- Tregitopes by Another Name?
- Artificial Intelligence / Human Intelligence & Immunoinformatics Workshop